Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations
Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.
The results they released were based on a randomised, double-blind, placebo-controlled Phase 2 study evaluating the treatments LY-CoV555 as a monotherapy and in combination with LY-CoV016, which bind with COVID-19’s spike protein. The combination met the primary endpoint of reducing the viral load, with most patients, including those receiving placebo, demonstrating near complete viral clearance by day 11. The company is working towards publishing this data in peer-reviewed journals.
Daniel Skovronsky, Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories, said: “Our teams have worked tirelessly the last seven months to discover and develop these potential antibody treatments. We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes. Lilly is diligently working with regulators around the world to make these treatments available.”
Based on this data, the company said it has submitted an Emergency Use Authorization for its single use antibody therapy and expected to submit one for its combination therapy in November. It plans to have one million doses of its monotherapy ready in late December.
Prior to an approval, the only way for a patient to get access to these treatments would be to participate in the clinical trials.
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT …
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …